Genetics and Treatment Type Influence Risk of Secondary Cancer Following Childhood Therapy

In a groundbreaking study that promises to reshape how physicians manage long-term care for childhood cancer survivors, researchers at St. Jude Children’s Research Hospital have unveiled compelling evidence that genetic predisposition plays a pivotal role alongside prior cancer treatments in determining the risk of developing secondary cancers. This research, published in the esteemed journal The Lancet Oncology, meticulously quantifies the relative contributions of therapy exposures and inherited genetic factors to the development of subsequent malignancies—a primary cause of mortality among long-term survivors. Drawing on extensive data from more than 10,000 survivors enrolled in the St. Jude Lifetime Cohort Study (St. Jude LIFE) and the Childhood Cancer Survivor Study (CCSS), this analysis provides one of the most comprehensive perspectives to date on the multifactorial origins of secondary cancer risk in pediatric oncology survivors.

Historically, the focus on second cancer risk has heavily emphasized the adverse late effects of treatments such as radiation and chemotherapy. While it has long been appreciated that exposure to ionizing radiation elevates cancer risk, this study contextualizes radiation as the most significant contributor, responsible for approximately 40% or more of the total risk burden for secondary cancers. The findings reaffirm concerns about radiation-induced oncogenesis and underscore ongoing clinical efforts to minimize radiation doses or eliminate radiation therapy when feasible, leveraging advances in targeted treatments that reduce collateral tissue damage.

Beyond radiation, the role of chemotherapy in second cancer risk emerges as more heterogeneous and dependent on the specific cancer subtype. The research demonstrates that chemotherapeutic agents contribute between 8% and 35% of the risk for subsequent malignancies. This variability reflects the diverse mechanisms by which different chemotherapy drugs may induce mutagenesis or impair DNA repair processes, which are intricately linked to oncogenesis years after treatment completion. While chemotherapy’s late effects have been documented extensively, their relative contribution compared to other factors has been less clear until now.

Perhaps the most striking revelation of this study lies in the elucidation of genetic factors influencing second cancer risk. Employing polygenic risk scoring (PRS)—a method that aggregates the effects of hundreds of common genetic variants associated with cancer susceptibility in the general population—investigators quantified the impact of inherited genetic predisposition on the development of subsequent neoplasms. Their results indicate that, contingent on cancer type, polygenic risk scores account for 5% to 37% of secondary cancer risk. This degree of influence rivals or in some cancers exceeds the contribution made by chemotherapy, challenging longstanding assumptions within pediatric oncology that genetics played a subordinate role.

These findings elevate the potential utility of genetic risk profiling in clinical survivorship care. Although polygenic risk scores have historically exhibited limited precision for predicting disease in general populations, their predictive value may be notably enhanced in childhood cancer survivors due to the interaction between inherited vulnerabilities and past therapeutic exposures. Tailoring surveillance protocols and preventive strategies according to individualized genetic risk profiles, combined with treatment histories, could herald a new era of personalized survivorship management aimed at early detection and prevention of secondary malignancies.

Intriguingly, lifestyle factors such as diet and physical activity, often lauded for their cancer-preventive potential in the general population, appeared to contribute minimally—only 1% to 6%—to second cancer risk within this cohort. It is important, however, to contextualize this finding within the demographics of the study participants, most of whom were in their twenties and thirties, an age range that may be too early to fully manifest lifestyle-related carcinogenic influences. Nevertheless, the importance of healthy behaviors remains undiminished for mitigating other late effects of childhood cancer treatment, including cardiovascular disease and metabolic disorders.

The study’s comprehensive dataset, encompassing genetic sequencing of over 12,000 survivors and detailed treatment exposure metrics, is unmatched in scope and depth in North America. Such a robust cohort enabled the application of advanced epidemiological models to parse the relative influences of diverse risk factors with unprecedented granularity. Co-author Dr. Gregory Armstrong emphasized that the synergy of the St. Jude LIFE and CCSS cohorts catalyzed breakthroughs not otherwise possible, highlighting the indispensable value of long-term, multi-institutional survivor registries for advancing precision medicine.

Clinically, these findings necessitate a paradigm shift. Past clinical guidelines for secondary cancer surveillance predominantly focused on the intensity and modality of prior cancer therapies. Now, incorporating genetic predisposition offers a more nuanced risk stratification framework. Patients harboring strong genetic susceptibilities could benefit from more rigorous and frequent monitoring, potentially enabling the earlier interception of secondary tumors when treatment efficacy is maximized. Conversely, survivors with lower combined risk profiles may avoid unnecessary screening burdens, optimizing resource allocation and minimizing patient anxiety.

Moreover, empowering survivors with knowledge of their personalized risk profiles could foster proactive engagement with healthcare providers and reinforce adherence to recommended screening regimens. This democratization of genetic and treatment exposure information aligns with the broader movement towards patient-centered care and shared decision-making, elements increasingly regarded as pillars of effective long-term survivorship programs.

The research team, led by first author Achal Neupane alongside experts including Siddhant Taneja, Jennifer French, and Yutaka Yasui, performed rigorous statistical analyses encompassing genetic variant testing, polygenic scoring, and epidemiologic modeling. Their interdisciplinary approach, drawing from genomics, oncology, and biostatistics, exemplifies how integrating multidimensional data sources can illuminate complex health outcomes.

Support for this landmark project was provided by multiple National Cancer Institute grants and the philanthropic efforts of ALSAC, underscoring the critical role of sustained funding in enabling transformative pediatric oncology research. Continued investment in longitudinal survivor cohorts and genomic technologies promises to deepen our understanding of therapy late effects and inherited risks, ultimately informing innovations in both treatment approaches and survivorship care.

In sum, this study represents a significant advancement in recognizing the intertwined contributions of genetics and cancer therapy to the risk of secondary malignancies in childhood cancer survivors. By quantifying these factors at the population level, it lays the groundwork for more individualized, genetically informed surveillance strategies, heralding a new era in survivorship medicine. As survivorship rates improve worldwide, addressing secondary health risks with precision will be vital to ensuring that these patients not only survive but thrive in the decades following their initial cancer battle.

News Publication Date: 28-May-2025

Web References:

• St. Jude Lifetime Cohort Study: https://sjlife.stjude.org/
• St. Jude Children’s Research Hospital: https://www.stjude.org/